DAFNA Capital Management LLC Nathan Fischel

Los Angeles, CA 20 processed 13Fs on this site, 2021 Q3 to 2026 Q2

$524M
88 holdings
2026 Q2
+19.1% QoQ
Top 5 40.2%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 88 holdings

Top 5 40.2%, top 10 56.2%

AUM over time

2026 Q2 $524M +19.1% QoQ

Q3 2021

Q1 2022

Q1 2023

Q1 2024

Q1 2025

Q1 2026

Book

2022 Q1 2021 Q4, filed 16 May, long equity only

Download CSV Download Excel All activity


STXS, Stereotaxis	13.30%	Hold	13,680,554	$3.73	$51M	—	—
XBI, SPDR SP Biotech ETF	6.31%	New	269,500	$89.88	$24M	+269,500	+$24M
FATE, Fate Therapeutics	5.06%	Add +34.6%	500,930	$38.77	$19M	+128,770	−$2.4M
Blueprint Medicines	4.10%	Add +19.0%	246,280	$63.88	$16M	+39,369	−$6.4M
Adicet Bio	3.73%	Reduce −2.4%	715,872	$19.97	$14M	−17,300	+$1.5M
NDAQ, Nasdaq Omx	3.48%, was 1.57%	Add +150.6%	102,500	$130.30	$13M	+61,600	+$7.1M
XENE, Xenon Pharmaceuticals	3.03%, was 3.16%	Reduce −5.6%	380,163	$30.57	$12M	−22,504	−$957K
Karuna Therapeutics	2.71%, was 2.39%	Add +13.3%	82,053	$126.78	$10M	+9,630	+$916K
DXCM, DexCom	2.42%	Hold	18,138	$511.58	$9.3M	—	—
BHVN, Biohaven	2.40%, was 2.01%	Add +33.6%	77,600	$118.57	$9.2M	+19,500	+$1.2M
NBIX, Neurocrine Biosciences	2.04%	Hold	83,655	$93.75	$7.8M	—	—
CYTK, Cytokinetics	2.03%, was 1.54%	Add +57.7%	211,495	$36.81	$7.8M	+77,401	+$1.7M
NRIX, Nurix Therapeutics	1.98%	Add +77.4%	543,344	$14.01	$7.6M	+237,024	−$1.3M
Morphic	1.90%	Hold	181,467	$40.15	$7.3M	—	—
Cardiovascular Systems	1.69%	Hold	286,988	$22.60	$6.5M	—	—
SNDX, Syndax Pharmaceuticals	1.68%, was 1.63%	Add +25.4%	371,987	$17.38	$6.5M	+75,452	−$26K
Merus	1.62%	Add +3.9%	234,989	$26.44	$6.2M	+8,900	−$977K
Sage Therapeutics	1.56%	Hold	180,306	$33.10	$6M	—	—
RVMD, Revolution Medicines	1.54%, was 1.34%	Add +9.4%	232,101	$25.51	$5.9M	+19,870	+$579K
IDYA, Ideaya Biosciences	1.43%	Add +6.5%	490,061	$11.19	$5.5M	+30,000	−$5.4M
Cymabay Therapeutics	1.37%, was 1.52%	Reduce −5.3%	1,692,569	$3.11	$5.3M	−95,000	−$778K
Iveric Bio	1.31%, was 1.16%	Add +8.2%	298,476	$16.83	$5M	+22,500	+$409K
Natus Medical	1.31%	Hold	190,635	$26.28	$5M	—	—
APLS, Apellis Pharmaceuticals	1.24%	New	93,935	$50.81	$4.8M	+93,935	+$4.8M
ATRC, Atricure	1.23%	Hold	72,029	$65.67	$4.7M	—	—
RCUS, Arcus Biosciences	1.19%	Add +23.9%	145,217	$31.56	$4.6M	+28,017	−$160K
ALEC, Alector	1.09%, was 0.81%	Add +88.6%	292,747	$14.25	$4.2M	+137,500	+$966K
Otonomy	0.94%, was 1.15%	Reduce −31.9%	1,497,514	$2.40	$3.6M	−702,783	−$983K
ASND, Ascendis Pharma A/s	0.94%, was 0.37%	Add +178.3%	30,612	$117.37	$3.6M	+19,612	+$2.1M
Mirati Therapeutics	0.91%	New	42,700	$82.22	$3.5M	+42,700	+$3.5M
EWTX, Edgewise Therapeutics	0.90%	New	356,750	$9.70	$3.5M	+356,750	+$3.5M
IPSC, Century Therapeutics	0.84%, was 0.40%	Add +156.5%	256,892	$12.59	$3.2M	+156,757	+$1.6M
ARAY, Accuray	0.81%	Hold	941,800	$3.31	$3.1M	—	—
Pardes Biosciences	0.79%	Add +80.4%	421,157	$7.22	$3M	+187,657	−$781K
TCOM, Field Trip Health	0.77%, was 0.21%	Add +542.8%	2,191,308	$1.34	$2.9M	+1,850,408	+$2.1M
Iteos Therapeutics	0.75%, was 0.63%	Add +65.1%	89,298	$32.18	$2.9M	+35,208	+$356K
Kalvista Pharmaceuticals	0.73%	Hold	190,663	$14.74	$2.8M	—	—
Rigel Pharmaceuticals	0.70%, was 0.59%	Add +1.9%	896,100	$2.99	$2.7M	+17,100	+$350K
LKFT, Galapagos	0.69%	Hold	42,675	$62.03	$2.6M	—	—
AXGN, Axogen	0.69%	Hold	332,103	$7.94	$2.6M	—	—
Aerie Pharmaceuticals	0.69%	Hold	289,040	$9.10	$2.6M	—	—
Affimed	0.65%	Hold	571,282	$4.37	$2.5M	—	—
F-Star Therapeutics	0.64%	Hold	693,785	$3.55	$2.5M	—	—
BCYC, Bicycle Therapeutics	0.61%	New	53,200	$43.87	$2.3M	+53,200	+$2.3M
Holding	0.57%	Hold	160,983	$13.50	$2.2M	—	—
AUTL, Autolus Therapeutics	0.54%	New	496,150	$4.17	$2.1M	+496,150	+$2.1M
Surface Oncology	0.52%, was 0.38%	Add +115.9%	680,000	$2.94	$2M	+365,000	+$493K
KURA, Kura Oncology	0.47%, was 0.39%	Add +2.3%	113,329	$16.08	$1.8M	+2,500	+$270K
Dice Therapeutics	0.47%	New	94,000	$19.13	$1.8M	+94,000	+$1.8M
BWAY, Brainsway	0.45%	Hold	200,000	$8.73	$1.7M	—	—
BMEA, Biomea Fusion	0.45%	Add +22.3%	383,923	$4.46	$1.7M	+70,000	−$627K
Radius Health	0.44%	Hold	191,978	$8.83	$1.7M	—	—
Macrogenics	0.44%, was 0.36%	Add +113.3%	192,000	$8.81	$1.7M	+102,000	+$247K
COGT, Cogent Biosciences	0.44%	Hold	223,554	$7.49	$1.7M	—	—
Kinnate Biopharma	0.43%	Add +39.2%	148,151	$11.26	$1.7M	+41,698	−$218K
Regulus Therapeutics	0.43%	Hold	5,555,555	$0.2981	$1.7M	—	—
NGM Biopharmaceuticals	0.43%, was 0.36%	Add +33.8%	107,653	$15.25	$1.6M	+27,168	+$217K
Immunocore	0.42%	New	53,878	$29.90	$1.6M	+53,878	+$1.6M
Holding	0.42%	Add +28.0%	59,452	$26.85	$1.6M	+13,000	−$620K
Mersana Therapeutics	0.37%, was 0.22%	Add +151.5%	352,763	$3.99	$1.4M	+212,500	+$536K
Venus Concept	0.36%, was 0.42%	Reduce −0.8%	968,187	$1.43	$1.4M	−7,500	−$274K
Mereo Biopharma Group	0.36%	Add +8.0%	1,216,613	$1.12	$1.4M	+90,000	−$440K
VKTX, Viking Therapeutics	0.35%	Hold	447,400	$3.00	$1.3M	—	—
89bio	0.32%	Add +124.0%	324,053	$3.77	$1.2M	+179,400	−$669K
Holding	0.28%	Add +0.1%	1,767,146	$0.6027	$1.1M	+2,300	−$3.6M
GH Research	0.26%	New	55,000	$18.29	$1M	+55,000	+$1M
CMPS, Compass Pathways	0.25%	New	74,890	$12.89	$965K	+74,890	+$965K
Neuronetics	0.25%	Hold	313,717	$3.03	$951K	—	—
Theseus Pharmaceuticals	0.24%, was 0.31%	Reduce −17.8%	80,124	$11.53	$924K	−17,376	−$312K
Nextcure	0.24%	Hold	187,696	$4.86	$912K	—	—
BDTX	0.23%	Add +52.2%	313,600	$2.77	$869K	+107,500	−$230K
WVE, Wave Life Sciences	0.20%	Hold	390,161	$2.00	$780K	—	—
Genfit	0.20%, was 0.08%	Add +210.9%	187,940	$4.00	$752K	+127,492	+$450K
Adaptimmune Therapeutics	0.19%, was 0.13%	Add +157.6%	351,064	$2.06	$723K	+214,798	+$212K
Vigil Neuroscience	0.18%	New	99,754	$7.03	$701K	+99,754	+$701K
Sutro Biopharma	0.18%, was 0.17%	Add +88.2%	84,700	$8.22	$696K	+39,700	+$26K
PHVS, Pharvaris	0.16%	Reduce −5.7%	34,615	$18.14	$628K	−2,105	+$100K
Lava Therapeutics	0.16%	Hold	139,332	$4.40	$613K	—	—
Harpoon Therapeutics	0.14%	Hold	105,163	$4.97	$523K	—	—
Phasebio Pharmaceuticals	0.13%	Hold	378,611	$1.32	$500K	—	—
INGN, Inogen	0.13%	Hold	15,000	$32.40	$486K	—	—
SCYX, Scynexis	0.12%	Hold	121,242	$3.91	$474K	—	—
Masimo	0.11%	Hold	3,000	$145.67	$437K	—	—
Compugen	0.11%, was 0.22%	Reduce −35.4%	130,202	$3.22	$419K	−71,300	−$447K
MDGL, Madrigal Pharmaceuticals	0.08%, was 0.12%	Reduce −44.6%	3,100	$98.06	$304K	−2,500	−$171K
CMPX, Compass Therapeutics	0.07%	Hold	196,091	$1.37	$269K	—	—
Aslan Pharmaceuticals	0.06%, was 0.21%	Reduce −66.7%	243,720	$0.8986	$219K	−488,780	−$601K
Holding	0.06%, was 0.05%	Add +75.0%	140,000	$1.54	$216K	+60,000	+$20K
LRMR, Larimar Therapeutics	0.05%, was 0.19%	Reduce −28.8%	49,996	$4.04	$202K	−20,181	−$555K
Surgalign	0.05%	Hold	579,710	$0.3036	$176K	—	—
Infinity Pharmaceuticals	0.04%, was 0.13%	Reduce −49.1%	120,097	$1.14	$137K	−116,063	−$394K
ANNX, Annexon	0.02%	Hold	30,796	$2.73	$84K	—	—

Showing top 50 of 92 by value

Exits / last held

Gone since 2021 Q4, shown at their last reported size.

Stock	% of portfolio	Recent activity	Reported price*	Value	Share change	$ change
Arena Pharmaceuticals	2.80%	Exit	$92.94	$11M	−119,615	−$11M
Holding	0.19%	Exit	$2.33	$747K	−320,444	−$747K
PRQR, Proqr Therapeutics	0.17%	Exit	$8.01	$685K	−85,476	−$685K
Bolt Biotherapeutics	0.12%	Exit	$4.90	$490K	−100,000	−$490K

Filings history

20 periods, with AUM normalized

Newest 13Fs

Period	Holds	AUM	QoQ	Form	Filed	Filing ID
2026 Q2	88	$524M	+19.1%	13F-HR	8/14/2026	000138993326000006
2026 Q1	83	$440M	+2.1%	13F-HR	5/15/2026	000138993326000004
2025 Q4	77	$431M	+6.4%	13F-HR	2/17/2026	000138993326000002
2025 Q3	75	$405M	+11.9%	13F-HR	11/14/2025	000138993325000008
2025 Q2	76	$362M	+2.5%	13F-HR	8/14/2025	000138993225000011
2025 Q1	83	$353M	−10.2%	13F-HR	5/15/2025	000138993325000002
2024 Q4	82	$393M	−7.1%	13F-HR	2/14/2025	000138993225000004
2024 Q3	84	$423M	+1.0%	13F-HR	11/14/2024	000138993224000020
2024 Q2	83	$419M	−4.6%	13F-HR	8/14/2024	000138993224000016
2024 Q1	72	$439M	+5.3%	13F-HR	5/15/2024	000138993224000012
2023 Q4	76	$417M	+29.9%	13F-HR	2/14/2024	000138993224000004
2023 Q3	75	$321M	−12.3%	13F-HR	11/14/2023	000138993223000010
2023 Q2	73	$366M	+9.6%	13F-HR	8/14/2023	000138993323000008
2023 Q1	72	$334M	−5.9%	13F-HR	5/15/2023	000138993323000006
2022 Q4	79	$355M	−4.6%	13F-HR	2/14/2023	000138993323000002
2022 Q3	87	$372M	+1.4%	13F-HR	11/14/2022	000138993322000010
2022 Q2	90	$367M	−4.4%	13F-HR	8/15/2022	000138993322000008
2022 Q1	94	$384M	−3.5%	13F-HR	5/16/2022	000138993322000006
2021 Q4	87	$398M	+5.6%	13F-HR	2/14/2022	000138993322000002
2021 Q3	80	$377M	—	13F-HR	11/15/2021	000138993321000011

About

DAFNA Capital Management LLC

20 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity: DAFNA Capital Management LLC
Notable person: Nathan Fischel
Location: Los Angeles, CA
All SEC filings: View on sec.gov